2014 International Union Against TB and Lung Disease World Conference
Date: October 30, 2014
Time: 18h00 - 22h00
Location: Hotel Diagonal Zero Barcelona

Community members, patient advocates and civil society members and representatives from affected communities express their disappointment with the Union's scholarship programme.

NC-005 trial tests a novel regimen of bedaquiline (Sirturo), pretomanid (formerly known as PA-824), and pyrazinamide; results could pave the way for a three-month TB treatment.

Two short treatment regimens for tuberculosis failed to match the standard 6 months of therapy in efficacy.

A civil society perspective of the response to multi & extensively drug resistant tuberculosis (M/XDR-TB) in the European region

The report details current shortcomings in the tuberculosis medicines market and opportunities to improve access to lifesaving TB treatment.

WHO’s "Global Tuberculosis Report 2014" shows that 9 million people developed TB in 2013, and 1.5 million died, including 360 000 people who were HIV positive.

TAG’s ninth annual Report on Tuberculosis Research Funding Trends shows that the foundation of the TB research enterprise is shakier than ever, setting back efforts to fight a disease that in 2012 killed 1.3 million people and caused 8.6 million to fall sick.

Pretomanid is a component of two new TB drug regimens being tested by TB Alliance for their ability to transform TB therapy, as well as future planned trials.

The Medicines Control Council has approved Janssen Pharmaceutica’s bedaquiline, the first drug specifically designed for treating multidrug-resistant tuberculosis (MDR-TB) to reach the market.